{"date":"2025-07-22","count":19,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6589-2025-07-22-2239-sifjug","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-07-22","time":"22:39:18","subject":"美國食品藥物管理局(FDA)已正式接受本公司授權夥伴Sandoz所提出生物相似藥EG12014(Trastuzumab Biosimilar)150毫克凍晶注射劑藥證申覆審查申請。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-07-22 22:39，「美國食品藥物管理局(FDA)已正式接受本公司授權夥伴Sandoz所提出生物相似藥EG12014(Trastuzumab 」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6879-2025-07-22-1927-1mfc4ho","company_id":"6879","company":"大江基因","market":"興櫃","industry":"生技醫療","date":"2025-07-22","time":"19:27:59","subject":"公告本公司除息基準日相關事宜","clause":"第31款","fact_date":"2025-07-22","cite_as":"公開資訊觀測站重大訊息：大江基因（6879），2025-07-22 19:27，「公告本公司除息基準日相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8436-2025-07-22-1920-1cvmh7w","company_id":"8436","company":"大江","market":"上櫃","industry":"生技醫療","date":"2025-07-22","time":"19:20:55","subject":"公告本公司發放盈餘現金股利及資本公積發放現金基準日","clause":"第14款","fact_date":"2025-07-22","cite_as":"公開資訊觀測站重大訊息：大江（8436），2025-07-22 19:20，「公告本公司發放盈餘現金股利及資本公積發放現金基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1783-2025-07-22-1916-1bl80n7","company_id":"1783","company":"和康生","market":"上市","industry":"生技醫療","date":"2025-07-22","time":"19:16:20","subject":"公告本公司調整2025年分派股東現金股利配息率","clause":"第14款","fact_date":"2025-07-22","cite_as":"公開資訊觀測站重大訊息：和康生（1783），2025-07-22 19:16，「公告本公司調整2025年分派股東現金股利配息率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1783-2025-07-22-1903-143edb0","company_id":"1783","company":"和康生","market":"上市","industry":"生技醫療","date":"2025-07-22","time":"19:03:12","subject":"公告本公司決定除息基準日相關事宜","clause":"第14款","fact_date":"2025-07-22","cite_as":"公開資訊觀測站重大訊息：和康生（1783），2025-07-22 19:03，「公告本公司決定除息基準日相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6748-2025-07-22-1809-1212jgy","company_id":"6748","company":"亞果生醫","market":"興櫃","industry":"生技醫療","date":"2025-07-22","time":"18:09:25","subject":"公告本公司膠原蛋白眼角膜基質獲得印度中央藥品標準控制組織（CDSCO）核發之「膠原蛋白眼角膜基質」人體臨床試驗核准通知書","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：亞果生醫（6748），2025-07-22 18:09，「公告本公司膠原蛋白眼角膜基質獲得印度中央藥品標準控制組織（CDSCO）核發之「膠原蛋白眼角膜基質」人體臨床試驗核准通知書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6469-2025-07-22-1754-1djpca5","company_id":"6469","company":"大樹","market":"上櫃","industry":"生技醫療","date":"2025-07-22","time":"17:54:43","subject":"本公司受邀參加臺灣生技產業高峰論壇","clause":"第12款","fact_date":"2025-07-25","cite_as":"公開資訊觀測站重大訊息：大樹（6469），2025-07-22 17:54，「本公司受邀參加臺灣生技產業高峰論壇」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6493-2025-07-22-1742-1l248wr","company_id":"6493","company":"雷虎生","market":"興櫃","industry":"生技醫療","date":"2025-07-22","time":"17:42:44","subject":"公告本公司114年現金增資收足股款暨增資基準日","clause":"第44款","fact_date":"2025-07-22","cite_as":"公開資訊觀測站重大訊息：雷虎生（6493），2025-07-22 17:42，「公告本公司114年現金增資收足股款暨增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4157-2025-07-22-1734-j4i37d","company_id":"4157","company":"太景*-KY","market":"上櫃","industry":"生技醫療","date":"2025-07-22","time":"17:34:27","subject":"公告本公司上櫃有價證券列為變更交易方法","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：太景*-KY（4157），2025-07-22 17:34，「公告本公司上櫃有價證券列為變更交易方法」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6662-2025-07-22-1710-altjhz","company_id":"6662","company":"樂斯科","market":"上櫃","industry":"生技醫療","date":"2025-07-22","time":"17:10:30","subject":"公告本公司董事會決議配息基準日暨現金發放日","clause":"第14款","fact_date":"2025-07-22","cite_as":"公開資訊觀測站重大訊息：樂斯科（6662），2025-07-22 17:10，「公告本公司董事會決議配息基準日暨現金發放日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6662-2025-07-22-1708-uszylj","company_id":"6662","company":"樂斯科","market":"上櫃","industry":"生技醫療","date":"2025-07-22","time":"17:08:28","subject":"公告本公司發言人、代理發言人及公司治理主管異動","clause":"第8款","fact_date":"2025-07-22","cite_as":"公開資訊觀測站重大訊息：樂斯科（6662），2025-07-22 17:08，「公告本公司發言人、代理發言人及公司治理主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4157-2025-07-22-1705-1avy7o1","company_id":"4157","company":"太景*-KY","market":"上櫃","industry":"生技醫療","date":"2025-07-22","time":"17:05:53","subject":"公告本公司重大訊息記者會新聞稿內容","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：太景*-KY（4157），2025-07-22 17:05，「公告本公司重大訊息記者會新聞稿內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6999-2025-07-22-1634-p67uuk","company_id":"6999","company":"瀚醫生技","market":"興櫃","industry":"生技醫療","date":"2025-07-22","time":"16:34:19","subject":"公告本公司內部稽核主管異動","clause":"第11款","fact_date":"2025-07-22","cite_as":"公開資訊觀測站重大訊息：瀚醫生技（6999），2025-07-22 16:34，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6796-2025-07-22-1622-12b7l6m","company_id":"6796","company":"晉弘","market":"上市","industry":"生技醫療","date":"2025-07-22","time":"16:22:48","subject":"公告本公司訂定配股配息基準日等相關事宜","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：晉弘（6796），2025-07-22 16:22，「公告本公司訂定配股配息基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6999-2025-07-22-1612-1qybse2","company_id":"6999","company":"瀚醫生技","market":"興櫃","industry":"生技醫療","date":"2025-07-22","time":"16:12:59","subject":"公告本公司董事會授權董事長訂定除權暨增資基準日相關事宜","clause":"第44款","fact_date":"2025-07-22","cite_as":"公開資訊觀測站重大訊息：瀚醫生技（6999），2025-07-22 16:12，「公告本公司董事會授權董事長訂定除權暨增資基準日相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4162-2025-07-22-1600-o0njjr","company_id":"4162","company":"智擎","market":"上櫃","industry":"生技醫療","date":"2025-07-22","time":"16:00:46","subject":"本公司研發中新藥PEP08，獲得澳洲人體試驗倫理審查委員會同意進行第一期人體臨床試驗，並已獲澳洲藥物管理局備查","clause":"第10款","fact_date":"2025-07-22","cite_as":"公開資訊觀測站重大訊息：智擎（4162），2025-07-22 16:00，「本公司研發中新藥PEP08，獲得澳洲人體試驗倫理審查委員會同意進行第一期人體臨床試驗，並已獲澳洲藥物管理局備查」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7759-2025-07-22-1518-1k6qcm8","company_id":"7759","company":"視航生醫","market":"興櫃","industry":"生技醫療","date":"2025-07-22","time":"15:18:49","subject":"本公司受邀參加2025亞洲生技大會舉辦之投資高峰論壇","clause":"第30款","fact_date":"2025-07-23","cite_as":"公開資訊觀測站重大訊息：視航生醫（7759），2025-07-22 15:18，「本公司受邀參加2025亞洲生技大會舉辦之投資高峰論壇」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6712-2025-07-22-1501-szyhik","company_id":"6712","company":"長聖","market":"上櫃","industry":"生技醫療","date":"2025-07-22","time":"15:01:11","subject":"本公司受邀參加由證券櫃檯買賣中心與元大證券聯合主辦之2025「臺灣生技產業高峰論壇」","clause":"第12款","fact_date":"2025-07-24","cite_as":"公開資訊觀測站重大訊息：長聖（6712），2025-07-22 15:01，「本公司受邀參加由證券櫃檯買賣中心與元大證券聯合主辦之2025「臺灣生技產業高峰論壇」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4157-2025-07-22-1430-svc53o","company_id":"4157","company":"太景*-KY","market":"上櫃","industry":"生技醫療","date":"2025-07-22","time":"14:30:44","subject":"公告本公司將召開投資人可參與之重大訊息記者會","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：太景*-KY（4157），2025-07-22 14:30，「公告本公司將召開投資人可參與之重大訊息記者會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}